Focus: Lumenis is a publicly-traded medical device company specializing in energy-based therapeutic platforms across ophthalmology, aesthetics, and surgical applications. With 1,001-5,000 employees and headquarters in Australia, they operate as an established player in the medical technology space.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Best fit for professionals seeking stable device-company roles in commercial, regulatory, or established-product engineering rather than early-stage drug discovery or clinical development careers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multi-indication flagship platform leveraged across dermatology and ophthalmology portfolios.
Help build intelligence for Lumenis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lumenis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Market-leading aesthetic laser device with continued use across multiple handpiece variants.
Surgical platform with applications in urology leveraging holmium:YAG laser technology.
Multi-application radiofrequency fractional system expanding across aesthetics and clinical dermatology.
Specialized intense pulsed light system focused on eyelid and ocular surface disease.
New Year. New Hair. FoLix(TM) – The first and only FDA-cleared non-invasive laser for hair loss is HERE! - Medianet News Hub
New Year. New Hair. FoLix(TM) – The first and only FDA-cleared non-invasive laser for hair loss is HERE! Medianet News Hub
Treatment Type Analysis - Market.us
Treatment Type Analysis Market.us
Recent peer-reviewed publications with author affiliations at this company
The potential benefits of periorbital transcutaneous electrical stimulation for the management of dry eye disease.
Multi-Frequency RF Combined with Intense Pulsed Light Improves Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction.
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo